| Iyuzeh (U.S.N.L.M.) | |
|---|---|
| Dosing | 1 drop qpm (optimal), (AM dosing is considered acceptable.) |
| Chem Specs | latanoprost 0.005% |
| Quantities | 30 single dose containers (0.2 mL each) |
| Cost | 371.00 / 30 dose carton |
| Class | prostaglandin F2α analog (as an isopropyl ester prodrug) |
| Action | Increased uveoscleral aqueous outflow (possibly by loosening intercellular spaces.) 28% - 30% IOP reduction |
| Usage | Indicated for reduction of IOP in open angle glaucoma or ocular hypertension. IOP reduction starts in 3-4 hours. Maximum effect in 8–12 hours. |
| Side Effects | Generally less hyperemia, less pigmentation of iris, lids, and lashes than Lumigan. Possible cystoid macular edema in pseudophakes and/or aphakes. May exacerbated iritis/uveitis. Possible reactivation of herpes simplex and zoster. Dry eye-like surface inflammation observed in mice. Avoid with inflammatory glaucomas and surface eye disease. |
| Contraindications | Hypersensitivity to latanoprost or any other ingredient in the product. |
| Pediatric use | Safety and effectiveness in pediatric patients have not been established. Has been used in children as young as 5 yrs without notable problems. |
| Pregnancy | Category C Embryofetal lethality shown in rats and rabbits at clinically relevant doses. |
| Preservative free single use containers. Contact lenses may be reinserted 15 minutes after administration |